Genomics

Dataset Information

0

Cancer-associated IDH1 promotes growth and resistance to targeted therapies in the absence of mutation


ABSTRACT: Oncogenic mutations in two isocitrate dehydrogenase (IDH)-encoding genes (IDH1 and IDH2) have been identified in acute myelogenous leukemia, low-grade glioma, and secondary glioblastoma (GBM). Our in silico and wet-bench analyses indicate that non-mutated IDH1 mRNA and protein are commonly overexpressed in primary GBM. We show that genetic and pharmacologic inactivation of IDH1 decreases GBM cell growth, promotes a more differentiated tumor cell state, increases apoptosis in response to targeted therapies, and prolongs survival of animal subjects bearing patient-derived xenografts (PDXs). On a molecular level, diminished IDH1 activity results in reduced a-ketoglutarate (aKG) and NADPH production, paralleled by deficient carbon flux from glucose or acetate into lipids, exhaustion of reduced glutathione, increased levels of reactive oxygen species (ROS), and enhanced histone methylation and differentiation marker expression. These findings suggest that IDH1 upregulation represents a common metabolic adaptation by GBM to support macromolecular synthesis, aggressive growth, and therapy resistance.

ORGANISM(S): Homo sapiens

PROVIDER: GSE98849 | GEO | 2018/03/13

REPOSITORIES: GEO

Similar Datasets

| E-GEOD-57002 | biostudies-arrayexpress
2014-04-30 | GSE57002 | GEO
2012-06-11 | GSE32079 | GEO
| E-GEOD-30835 | biostudies-arrayexpress
| E-MTAB-11031 | biostudies-arrayexpress
| E-GEOD-32079 | biostudies-arrayexpress
| E-GEOD-32286 | biostudies-arrayexpress
2014-05-02 | GSE54077 | GEO
| E-GEOD-54077 | biostudies-arrayexpress
2022-05-13 | GSE202696 | GEO